Literature DB >> 10481831

Dose response of adrenocorticotropin and cortisol to the CCK-B agonist pentagastrin.

J L Abelson1, I Liberzon.   

Abstract

Cholecystokinin (CCK) is an abundant neurotransmitter in brain. Its functional significance in humans is incompletely understood, but it may modulate activity in the hypothalamic-pituitary-adrenal (HPA) axis. To explore this hypothesis, we examined the effects of varying doses (0 to 0.8 microgram/kg) of the CCK-B agonist pentagastrin on adrenocorticotropin (ACTH) and cortisol release in healthy human subjects. We also examined anxiety, heart rate (HR), and blood pressure (BP) responses. Pentagastrin induced large (up to 520% increase over baseline), significant and very rapid, dose-dependent elevations in ACTH and cortisol levels. Significant elevations in HR and BP were seen at all doses, without clear dose-response relationships. Anxious distress and symptom responses were also somewhat dose dependent; but hormonal responses were more robustly linked to pentagastrin dose than to these subjective measures. The HPA axis response to the CCK-B agonist pentagastrin may be a direct pharmacological effect. Further work is needed to determine the mechanisms and the physiological significance of CCK-mediated modulation of the human neuroendocrine stress axis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10481831     DOI: 10.1016/S0893-133X(98)00124-9

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  10 in total

1.  Effects of perceived control and cognitive coping on endocrine stress responses to pharmacological activation.

Authors:  James L Abelson; Samir Khan; Israel Liberzon; Thane M Erickson; Elizabeth A Young
Journal:  Biol Psychiatry       Date:  2008-06-24       Impact factor: 13.382

2.  Effect of cholecystokinin on cytokines during endotoxic shock in rats.

Authors:  Y L Ling; A H Meng; X Y Zhao; B E Shan; J L Zhang; X P Zhang
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

Review 3.  Cholecystokinin hyperresponsiveness in functional dyspepsia.

Authors:  A S B Chua; P W N Keeling
Journal:  World J Gastroenterol       Date:  2006-05-07       Impact factor: 5.742

4.  Cognitive modulation of endocrine responses to CRH stimulation in healthy subjects.

Authors:  James L Abelson; Samir Khan; Elizabeth A Young; Israel Liberzon
Journal:  Psychoneuroendocrinology       Date:  2009-09-16       Impact factor: 4.905

5.  Effect of time of preparation on pentagastrin-induced symptom, endocrine and cardiovascular responses.

Authors:  Samir Khan; Hedieh Briggs; James Lawrence Abelson
Journal:  Psychiatry Res       Date:  2008-01-28       Impact factor: 3.222

6.  Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study.

Authors:  Daniela Eser; Cornelius Schüle; Thomas Baghai; Anette Floesser; Axel Krebs-Brown; Michaela Enunwa; Stephan de la Motte; Rolf Engel; Klaus Kucher; Rainer Rupprecht
Journal:  Psychopharmacology (Berl)       Date:  2007-02-23       Impact factor: 4.415

Review 7.  Neurobiology of panic and pH chemosensation in the brain.

Authors:  John A Wemmie
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

8.  The effects of CCK-8S on spatial memory and long-term potentiation at CA1 during induction of stress in rats.

Authors:  Malihe Sadeghi; Parham Reisi; Maryam Radahmadi
Journal:  Iran J Basic Med Sci       Date:  2017-12       Impact factor: 2.699

9.  Emotional perception modulated by an opioid and a cholecystokinin agonist.

Authors:  Katarina Gospic; Tove Gunnarsson; Peter Fransson; Martin Ingvar; Nils Lindefors; Predrag Petrovic
Journal:  Psychopharmacology (Berl)       Date:  2007-12-11       Impact factor: 4.415

10.  Effects of repeated treatment with cholecystokinin sulfated octapeptide on passive avoidance memory under chronic restraint stress in male rats.

Authors:  Malihe Sadeghi; Maryam Radahmadi; Parham Reisi
Journal:  Adv Biomed Res       Date:  2015-07-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.